4th DIA European Cardiac Safety Conference

25-26 October 2010 I Hotel Le Méridien, Nice, France

Programme Co-Chairs

Boaz Mendzelevski, Vice President of Cardiology, Medifacts International, United Kingdom

Borje Darpo, Associate Professor of Cardiology, Pharmaceutical Consultant, Sweden

Programme Committee

Pierre Jordaan, Senior Translational Medicine Expert, TM CardioVascular Profiling, Novartis Institute for Biomedical Research (NIBR), Switzerland

Krishna Prasad, Clinical Assessor, Consultant Cardiologist, MHRA, United Kingdom

Robert Wallis, Executive Director, Head of Centres of Emphasis, Drug Safety Research and Development, Pfizer Global R&D, USA

DIA®
www.diahome.org

Cardiovascular safety of new drugs has been at the center of public attention and concern for more than a decade. Since the release of the ICH-E14 guidance in May 2005 the industry, regulatory and academic debate evolved from a focus on a single dedicated and thorough QT (TQT) study to the broader aspects of developing robust and continuous non-clinical and clinical models to establish scientific and practical methods for cardiovascular risk assessment. While the TQT study is still the centre-piece of clinical QT assessment, there are several initiatives on-going, which look into the predictive value of alternative approaches, such as combining non-clinical data with intense QT assessment in early clinical studies. In addition, with the benefits of more data and better knowledge, drug-induced effects on other ECG parameters, such as the PR and QRS intervals, and on hemodynamic parameters, such as blood pressure, have gained attention as potential risk markers for adverse cardiovascular effects. These and other topics will be discussed at the forthcoming 4th DIA European Cardiac Safety conference, alongside presentations of new technologies, methodologies and novel biomarkers for early detection and risk management of drug related cardiovascular toxicity.

Key Topics

- The Future of Thorough QT Assessment - Where do we go from here?
- Cardiovascular Safety of Oncology and Biological Pharmaceutical Products
- Cardiovascular Safety Beyond the QT Interval - Drug effect on other ECG indices
- Drug Effect on Hemodynamic Parameters – Blood pressure and related indices
- Understanding Cardiovascular Risk as a Cause of Compound Attrition

Who Will Attend

- Drug Development and Clinical Research Managers and Associates
- Pharmaceutical Physicians and Medical Directors
- Safety Pharmacology and Nonclinical Scientists
- Drug Safety and Drug Surveillance Personnel
- Clinical Pharmacology Scientists
- Pharmacovigilance Managers
- Regulatory Affairs Managers
- Biostatisticians
- Data Managers
- IT/Technology Managers
- Outsourcing and Marketing Managers

FOR REGULAR PROGRAMME UPDATES, PLEASE VISIT WWW.DIAHOME.ORG

Exhibition

At this conference, DIA will provide an international platform for pharmaceutical industry support organisations to exhibit their materials and services. This yields increased networking opportunities for attendees. To obtain details on exhibiting space and facilities please contact:
Natacha Scholl at natacha.scholl@diaeurope.org

Contact: lucy.douglas@diaeurope.org or +41 61 225 51 51

REGISTER NOW!

www.diahome.org > “Conferences / Meetings” in the left hand navigation menu > “Find a Meeting” > “Keyword” 10113